二甲双胍
医学
2型糖尿病
怀孕
后代
妊娠期糖尿病
产科
体质指数
糖尿病
肥胖
人口
胰岛素
内分泌学
妊娠期
内科学
环境卫生
遗传学
生物
作者
C. Newman,Fidelma Dunne
标识
DOI:10.1097/aog.0000000000005705
摘要
Metformin is a commonly used drug in the treatment of type 2 diabetes and has been used to treat gestational diabetes since the 1970s. In pregnancy, its proven benefits include reduced gestational weight gain and reduced fetal size; some studies have shown reduced risk of cesarean delivery and lower rates of hypertension. Metformin can reduce the need for insulin therapy but does not eliminate such need in many patients. Despite these benefits, metformin crosses the placenta and has been associated with increases in the risk of giving birth to small-for-gestational-age neonates in some studies of individuals with type 2 diabetes in pregnancy. In addition, higher body mass index (BMI) z-scores have been observed among exposed offspring in some of the long-term follow-up studies. Nevertheless, metformin's low cost, ease of administration, and global reach make it a reasonable intervention in a population affected by rising rates of obesity and diabetes in pregnancy. Further follow-up studies are required to monitor the long-term health of exposed offspring.
科研通智能强力驱动
Strongly Powered by AbleSci AI